100706-药理学

肿瘤药理学
肿瘤代谢
肿瘤免疫

2002-09--2007-06   中国科学院上海药物研究所   博士
1998-09--2002-06   中国药科大学   本科

   

2013-01~现在, 中国科学院上海药物研究所, 研究员
2011-10~2012-12,中国科学院上海药物研究所, 副研究员
2011-03~2011-09,中国科学院上海药物研究所, 助理研究员
2008-01~2011-02,美国哈佛医学院Dana-Farber肿瘤研究所, 博士后
2002-09~2007-06,中国科学院上海药物研究所, 博士
1998-09~2002-06,中国药科大学, 本科

2015-01-01-今,药学学报青年编委,

高等药理学
分子靶向药物的研究现状及策略

   

（1） 药明康德生命化学研究奖, 其他, 2017
（2） 上海市科技系统青年五四奖章, 省级, 2017
（3） 上海市巾帼创新新秀奖暨上海市“三八红旗手”, 省级, 2016
（4） 施维雅青年药理学家奖, 其他, 2016
（5） 中源协和生命医学奖创新突破奖, 其他, 2016
（6） 中国科学院卢嘉锡青年人才奖, 部委级, 2013

（ 1 ） 丙酮酸脱氢酶激酶抑制剂及其应用, 2015, 第 1 作者, 专利号: 201510586458.4

（ 2 ） 一类具有激酶抑制活性的化合物、制备方法和用途, 2015, 第 4 作者, 专利号: 201510387962.1

（ 3 ） 一种新型激酶抑制剂的制备及其应用, 2015, 第 4 作者, 专利号: 201510279568.6

（ 4 ） 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途, 2014, 第 3 作者, 专利号: 201410250746.8

   

（1） Discovery of Novel Drug-like PHGDH Inhibitors to Disrupt Serine Biosynthesis for Cancer Therapy, JOURNAL OF MEDICINAL CHEMISTRY, 2023, 通讯作者
（2） Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis, CELL DEATH AND DIFFERENTIATION, 2022, 第 16 作者
（3） Metabolic Regulation of CD8(+) T Cells: From Mechanism to Therapy, ANTIOXIDANTS & REDOX SIGNALING, 2022, 通讯作者
（4） NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion, NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion, ACTA PHARMACEUTICA SINICA B, 2022, 通讯作者
（5） Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT, JOURNAL OF MEDICINAL CHEMISTRY, 2022, 第 4 作者
（6） SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors, CELL RESEARCH, 2022, 通讯作者
（7） Antitumor pharmacological research in the era of personalized medicine, Antitumor pharmacological research in the era of personalized medicine, ACTA PHARMACOLOGICA SINICA, 2022, 第 1 作者
（8） Discovery of Novel Pyrrolo2,3-dpyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors, JOURNAL OF MEDICINAL CHEMISTRY, 2022, 通讯作者
（9） Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer, JOURNAL OF MEDICINAL CHEMISTRY, 2022, 第 5 作者
（10） 代谢调控肿瘤微环境固有免疫应答机制研究进展, Metabolic regulation of innate immunity in cancer, 药学学报, 2022, 通讯作者
（11） Dihydro-beta-agarofuran-Type Sesquiterpenoids from the Seeds of Celastrus virens and Their Multidrug Resistance Reversal Activity against the KB/VCR Cell Line, JOURNAL OF NATURAL PRODUCTS, 2021, 第 4 作者
（12） Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 第 10 作者
（13） A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies, MOLECULAR CELL, 2021, 通讯作者
（14） Harnessing Genomic Stress for Antitumor Immunity, ANTIOXIDANTS & REDOX SIGNALING, 2021, 通讯作者
（15） Mutant isocitrate dehydrogenase driven metabolic reprogramming results in therapeutic vulnerability to lactate dehydrogenase inhibition, CANCER RESEARCH, 2020, 第11作者
（16） SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo (vol 351, pg 413, 2014), CANCER LETTERS, 2020, 第 6 作者
（17） 血管内皮细胞代谢与肿瘤血管新生研究进展, Research advancement in vascular endothelial cell metabolism and tumor angiogenesis, 药学学报, 2020, 第 3 作者
（18） Corrigendum to "SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo" Cancer Lett. 351 (2014) 143–50, CANCER LETTERS, 2020, 第 6 作者
（19） Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 第11作者
（20） A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer, CELL METABOLISM, 2019, 第 10 作者
（21） Identification of a new inhibitor of KRAS-PDE delta interaction targeting KRAS mutant nonsmall cell lung cancer, INTERNATIONAL JOURNAL OF CANCER, 2019, 第 8 作者
（22） Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer, NATURE COMMUNICATIONS, 2019, 通讯作者
（23） Fragment-based drug discovery of triazole inhibitors to block PDE delta-RAS protein-protein interaction, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 通讯作者
（24） Histone marks interplay at LIFR enhancer determines the response to HDAC inhibitors in breast cancer, CANCERRESEARCH, 2019, 第 5 作者
（25） 化疗药调控肿瘤免疫应答机制研究进展, Mechanistic advancement in chemotherapeutic agents modulated antitumor immune response, 药学学报, 2019, 第 3 作者
（26） EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells, ACTA PHARMACOLOGICA SINICA, 2019, 第 9 作者
（27） 代谢产物调控肿瘤信号通路的分子机制研究进展, Mechanisms of metabolite-triggered oncogenic signaling in cancer, 药学学报, 2019, 第 2 作者
（28） Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies, JOURNAL OF MEDICINAL CHEMISTRY, 2019, 第 5 作者
（29） Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy, ACTA PHARMACEUTICA SINICA B, 2018, 通讯作者
（30） Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors, CELL, 2018, 第 16 作者
（31） Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 通讯作者
（32） Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity, CELL DEATH & DISEASE, 2018, 第11作者
（33） Aberrant sialylation in cancer pathology and metastasis, a putative drug target candidate, ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 第 5 作者
（34） Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 通讯作者
（35） CREB orchestrates metabolic reprogramming in PDGFRA-addicted lung squamous cell cancer, CANCER RESEARCH, 2018, 第 3 作者
（36） Identification of Epigallocatechin-3-Gallate as an Inhibitor of Phosphoglycerate Mutase 1, FRONTIERS IN PHARMACOLOGY, 2017, 第 9 作者
（37） Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration, JOURNAL OF CANCER, 2017, 第 5 作者
（38） CimicifoetonesA and B, Dimeric Prenylindole Alkaloids as Black Pigments of Cimicifuga foetida, CHEMISTRY-AN ASIAN JOURNAL, 2017, 第 5 作者
（39） Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma, HEPATOLOGY, 2017, 第 5 作者
（40） Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase, CLINICAL CANCER RESEARCH, 2017, 其他（合作组作者）
（41） Development of the First Generation of Disulfide-Based Subtype Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors, JOURNAL OF MEDICINAL CHEMISTRY, 2017, 通讯作者
（42） Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 通讯作者
（43） Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition, CANCER LETTERS, 2017, 第 8 作者
（44） Exploiting histone deacetylases for cancer therapy: from hematological malignancies to solid tumors, SCIENCE CHINA-LIFE SCIENCES, 2017, 第 1 作者
（45） c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors, CLINICAL CANCER RESEARCH, 2017, 通讯作者
（46） Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 通讯作者
（47） 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib, FASEB JOURNAL, 2017, 第 9 作者
（48） Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells, JOURNAL OF CELL BIOLOGY, 2017, 通讯作者
（49） Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation, CELL RESEARCH, 2017, 通讯作者
（50） Crassins A-H, Diterpenoids from the Roots of Croton crassifolius, JOURNAL OF NATURAL PRODUCTS, 2017, 第 5 作者
（51） Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 第 4 作者
（52） Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2), BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 通讯作者
（53） Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer, CANCER CELL, 2016, 通讯作者
（54） The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma, TUMOR BIOLOGY, 2016, 第 5 作者
（55） One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates., ORGANIC & BIOMOLECULAR CHEMISTRY, 2016, 第 10 作者
（56） Phosphoglycerate Mutase 1 Promotes Cancer Cell Migration Independent of its Metabolic Activity., Oncogene, 2016, 
（57） Network modelling reveals the mechanism underlying colitis-associated colon cancer and identifies novel combinatorial anti-cancer targets, SCIENTIFIC REPORTS, 2015, 
（58） Lactate Dehydrogenase B Is Associated with the Response to Neoadjuvant Chemotherapy in Oral Squamous Cell Carcinoma, PLOS ONE, 2015, 第 8 作者
（59） 6-Methoxyethylamino-numonafide (MEAN) inhibits hepatocellular carcinoma as a single agent or in combination with sorafenib, CANCER RESEARCH, 2015, 第 7 作者
（60） (Z)3,4,5,4′-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level, SCIENTIFIC REPORTS, 2015, 第 10 作者
（61） DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro, DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro, 中国药理学报：英文版, 2015, 第 6 作者
（62） Acetylation at lysine 71 inactivates superoxide dismutase 1 and sensitizes cancer cells to genotoxic agents, ONCOTARGET, 2015, 通讯作者
（63） c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers, CANCER RESEARCH, 2015, 第 3 作者
（64） DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro, ACTA PHARMACOLOGICA SINICA, 2015, 第 6 作者
（65） JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification, CANCER RESEARCH, 2015, 第 15 作者
（66） SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-MET-Dependent Neoplastic Effects and Exerts Antitumor Activity, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 第 7 作者
（67） SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo, CANCER LETTERS, 2014, 第 6 作者
（68） Molecular-Dynamics-Simulation-Driven Design of a Protease-Responsive Probe for In-Vivo Tumor Imaging, ADVANCED MATERIALS, 2014, 第 7 作者
（69） Merremins A-G, Resin Glycosides from Merremia hederacea with Multidrug Resistance Reversal Activity, JOURNAL OF NATURAL PRODUCTS, 2014, 第 4 作者
（70） Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells, Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells, ACTA PHARMACOLOGICA SINICA, 2014, 第 6 作者
（71） Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 第 16 作者
（72） JG6, a novel marine-derived oligosaccharide, suppresses breast cancer metastasis via binding to cofilin, ONCOTARGET, 2014, 第 7 作者
（73） Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells, Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells, 中国药理学报：英文版, 2014, 第 6 作者
（74） Molecularly targeted cancer therapy: some lessons from the past decade, TRENDS IN PHARMACOLOGICAL SCIENCES, 2014, 第 1 作者
（75） Discovery and Optimization of 4,5-Diarylisoxazoles as Potent Dual Inhibitors of Pyruvate Dehydrogenase Kinase and Heat Shock Protein 90, JOURNAL OF MEDICINAL CHEMISTRY, 2014, 通讯作者
（76） O-GlcNAcylation of Cofilin Promotes Breast Cancer Cell Invasion, JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 第 6 作者
（77） Inhibition of the Nedd8 system sensitizes cells to DNA Inter-strand crosslinking agents, MOLECULAR CANCER RESEARCH, 2012, 第 2 作者
（78） Extensive Crosstalk between O -GlcNAcylation and Phosphorylation Regulates Akt Signaling, PLOS ONE, 2012, 第11作者
（79） D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase II alpha, INVESTIGATIONAL NEW DRUGS, 2011, 第 3 作者
（80） Naphthalimides Induce G2 Arrest Through the ATM-Activated Chk2-Executed Pathway in HCT116 Cells, NEOPLASIA, 2009, 第 3 作者
（81） Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins, MOLECULAR CANCER THERAPEUTICS, 2008, 第 1 作者
（82） Salvicine triggers DNA double-strand breaks and apoptosis by GSH-depletion-driven H 2O 2 generation and topoisomerase II inhibition, FREE RADICAL BIOLOGY AND MEDICINE, 2008, 第 5 作者
（83） Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo, CLINICAL CANCER RESEARCH, 2007, 第 1 作者
（84） DNA双链断裂损伤修复系统研究进展, Repair Pathways in Response to DNA Double-Strand Breaks, 生理科学进展, 2007, 第 1 作者
（85） 拓扑异构酶Ⅰ抑制剂研究进展, Developments of topoisomerase Ⅰ inhibitors in cancer chemotherapy, 中国新药杂志, 2007, 第 1 作者
（86） Chimmitecan, a novel 9-substituted camptothecin, is a promising anticancer drug candidate., CANCER RESEARCH, 2006, 第 1 作者
（87） 抗肿瘤药物新靶点, 中国处方药, 2006, 第 1 作者
（88） The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma, JNCI JOURNAL OF THE NATIONAL CANCER INSTITUTE, 第 14 作者

   

（ 1 ） 抗肿瘤候选新药希明替康临床研究及敏感人群探索, 负责人, 其他国际合作项目, 2015-01--2018-12
（ 2 ） 肺腺癌代谢生物标志物发现与抗耐药中药研发, 负责人, 其他国际合作项目, 2015-04--2018-03
（ 3 ） 肿瘤代谢关键激酶丙酮酸脱氢酶激酶（PDHK）抗肿瘤作用研究及敏感群体发现, 负责人, 国家任务, 2016-01--2019-12
（ 4 ） 肿瘤代谢药物药理学研究, 负责人, 国家任务, 2023-01--2027-12
（ 5 ） KRAS驱动非小细胞肺癌代谢依赖性机制研究, 负责人, 国家任务, 2020-01--2022-12
（ 6 ） 上海市2020年度优秀学术带头人项目, 负责人, 地方任务, 2020-06--2023-05
（ 7 ） 抗肿瘤新药敏感群体和耐药机制研究”创新研究群体, 参与, 国家任务, 2019-01--2024-12

（1）靶向肿瘤代谢的抗肿瘤药物研究   东方肿瘤分子诊断与靶向治疗学术会议   2017-10-28
（2）靶向肿瘤代谢的抗肿瘤药物研究   第十五届全国肿瘤药理与临床化疗学术会议   2017-04-28
（3）靶向肿瘤代谢的抗肿瘤药物研究   东方科技论坛-肿瘤代谢的关键科学问题及转化研究前沿研讨会   2016-06-20
（4）Targeting Cancer Metabolism for Cancer Therapy   2016年皇后镇分子生物学（上海）会议——药物发现与转化医学   2016-03-17